Wecome Pharmaceutical Co Ltd (300878) — Capital Reinvestment Ratio
Latest as of June 2025:
0.01x
Wecome Pharmaceutical Co Ltd (300878) has a Capital Reinvestment Ratio of 0.01x as of June 2025, meaning it reinvests 0% of its operating cash flow (CN¥50.89 Million) in capital expenditures (CN¥389.97K). See 300878 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.01x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥50.89 Million
CNY
Capital Expenditures
CN¥389.97K
CNY
Data as of
Jun 2025
Most recent filing
Wecome Pharmaceutical Co Ltd Capital Reinvestment Ratio (2013–2023)
This chart tracks Wecome Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 10 annual periods.
Annual Capital Reinvestment Ratio for Wecome Pharmaceutical Co Ltd (2013–2023)
Year-by-year Capital Reinvestment Ratio for Wecome Pharmaceutical Co Ltd from 2013 to 2023. For live market cap and broader valuation context, see Wecome Pharmaceutical Co Ltd market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 2.39x | CN¥58.29 Million | CN¥139.29 Million | ▲ +41.0% |
| 2022 | 1.70x | CN¥146.57 Million | CN¥248.44 Million | ▼ -52.4% |
| 2020 | 3.56x | CN¥42.81 Million | CN¥152.34 Million | ▲ +249.0% |
| 2019 | 1.02x | CN¥112.76 Million | CN¥114.98 Million | ▼ -37.7% |
| 2018 | 1.64x | CN¥105.57 Million | CN¥172.73 Million | ▲ +12.9% |
| 2017 | 1.45x | CN¥29.00 Million | CN¥42.04 Million | ▲ +202.7% |
| 2016 | 0.48x | CN¥100.15 Million | CN¥47.97 Million | ▼ -63.1% |
| 2015 | 1.30x | CN¥29.63 Million | CN¥38.48 Million | ▲ +46.9% |
| 2014 | 0.88x | CN¥46.01 Million | CN¥40.68 Million | ▲ +100.2% |
| 2013 | 0.44x | CN¥25.98 Million | CN¥11.48 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow